ECAP: The Neurocognitive Architecture of Endocannabinoid-Associated Pathways

The Endocannabinoid-Associated Pathways (ECAP) model offers a potentially transformative understanding of Cannabis sativa's complex effects. It moves beyond the traditional Endocannabinoid System (ECS) to map how cannabinoid signaling operates within a broader, interconnected network of molecular pathways.

Publication Status

• Format: White paper (self-published preprint)
• License: CC BY 4.0
• DOI: 10.5281/zenodo.17467525
• Citations: 100+ peer-reviewed sources spanning 1993-2023

Executive Summary

ECAP conceptualizes the traditionally defined ECS not as an isolated entity, but as a central regulatory hub deeply embedded within a larger, interconnected network of molecular pathways. The full range of cannabis's effects arises from the concerted action of its constituents on this broader network.

The framework encompasses:

• Canonical cannabinoid receptors (CB1, CB2)
• Non-canonical receptors and ion channels (TRPV1, GPR55, GPR18, GPR119, PPARs, GlyRs, 5-HT3A)
• Interacting neurotransmitter systems (dopaminergic, serotonergic, GABAergic, glutamatergic, cholinergic, noradrenergic)
• Modulated hormonal axes (HPA axis, oxytocinergic system)
• The influence of phytocannabinoids and terpenes (the "entourage effect" recontextualized mechanistically)
• The gut-brain-immune axis and inflammatory pathways

How the ECAP Model Is Organized

The paper is structured in 11 sections covering the full architecture:

Sections 1-2: Core Receptor Landscape. CB1 and CB2 receptors, their neurocognitive and physiological roles, plus the expanded non-canonical targets (TRPV1 channels for pain and sensory processing, GPR55 for neuromodulation and metabolism, PPARs, GlyRs, and voltage-gated channels).

Sections 3-4: Neurotransmitter and Hormonal Integration. How cannabinoid signaling interacts with dopaminergic pathways (reward, motivation), serotonergic pathways (mood, anxiety), GABAergic and glutamatergic balance (excitation/inhibition), the HPA axis (stress response, cortisol), and the oxytocin system (social bonding, trust).

Section 5: Creativity, Action, and Performance (CAP). A speculative but structured extension mapping how specific ECAP pathway activations may modulate neurocognitive states conducive to enhanced creativity (via dopamine, 5-HT1A, CB1/DMN modulation), optimized action (via dopamine, HPA axis, noradrenergic pathways), and peak performance (via GABA/glutamate balance, oxytocin, ACh). Explicitly labeled as requiring substantial empirical validation.

Sections 6-7: Terpenes and the Gut-Brain-Immune Axis. How terpenes (limonene, pinene, linalool, myrcene, beta-caryophyllene) act as aromatic modulators across the ECAP network. How cannabinoid influence on gut microbiota, intestinal permeability, and neuroinflammation feeds back into the system.

Sections 8-11: Applications, Research Gaps, and Conclusions. Practical use cases (chronic pain, anxiety, sleep, focus, neurocognitive recovery), clinical applications (neuropsychiatric, neurodegenerative, inflammatory, pediatric epilepsy, oncology supportive care), and a call for interdisciplinary research.

Figure A compares pain score trajectories across three ECAP-aligned intervention groups over a 12-week period.

Key Propositions

ECAP advances several testable propositions:

1. The Network Model. Cannabis effects arise from concerted action on an integrated network beyond CB1/CB2, including TRPV1, GPR55, PPARs, neurotransmitter systems, hormonal axes, and the gut-brain-immune axis.

2. Mechanistic Entourage Effect. The entourage effect is explained by parallel activations across multiple, distinct ECAP pathways converging on shared signaling molecules, neural circuits, or physiological processes.

3. Biased Agonism. Different cannabis constituents can "steer" CB1 signaling towards specific ECAP sub-pathways via functional selectivity, explaining why some experiences are anxiolytic while others are anxiogenic.

4. Chemovar Fingerprints. Specific cannabinoid/terpene ratios create unique "ECAP activation fingerprints" that produce predictable and distinct outcomes.

5. Individual Variability. The ultimate effect is an emergent property of the interaction between a product's ECAP engagement profile and the individual's pre-existing ECAP baseline conditions (genetics, gut microbiome, neurotransmitter tone, HPA axis reactivity).

6. The CAP Engine. Specific ECAP pathway activations can modulate states conducive to enhanced Creativity, optimized Action, and peak Performance. (Explicitly speculative, requiring rigorous validation.)

7. Gut-Microbiome Responsivity. Individual differences in gut microbiota composition could be a major predictor of cannabis response, and "gut typing" could become as important as pharmacogenomic testing.

Selected Figures

Figure B shows stress and anxiety levels across Standard, Enhanced, and AI-Assisted ECAP-aligned plans.

System coverage snapshot showing pathway distribution across ECAP domains. Note: the CAP (Creativity/Action/Performance) domain is a speculative extension requiring further validation.

Figure C presents a radar chart comparing two hypothetical chemovar fingerprints across Creativity, Action, Recovery, and Clarity dimensions.

AI-Augmented Research Methodology

ECAP was built with AI as a research partner. AI helped organize over 100 sources, identify cross-pathway patterns, and generate initial hypothesis structures. Every connection in the model was validated against peer-reviewed literature by a licensed pharmacist with 18 years of clinical experience. AI did not replace pharmacological judgment. It accelerated the synthesis.

Who This Is For

• Cannabis brands and product teams who need science-backed formulation guidance
• Clinicians and mental health professionals who want a structured framework for understanding cannabinoid interactions
• Researchers and students looking for testable propositions and a systems-level map

What Comes Next

ECAP is the first of three interconnected research publications:

1. ECAP (released) - The neurocognitive architecture of endocannabinoid-associated pathways
2. The A2 System (working paper) - A unified framework mapping attention and intention onto the Expected Free Energy equation
3. The Abundance Thesis (in development) - Evidence-based economic empowerment pathways

Access the Research

Download Full Paper (PDF) via Zenodo DOI: 10.5281/zenodo.17467525

Licensed under CC BY 4.0. Figures may be reused with attribution.

Selected References

• Ben-Shabat, S., et al. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 353(1), 23-31.
• Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344-1364.
• Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids. British Journal of Pharmacology, 153(2), 199-215.
• Zou, S., & Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. International Journal of Molecular Sciences, 19(3), 833.
• Gertsch, J., et al. (2008). Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences, 105(26), 9099-9104.
• De Petrocellis, L., et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479-1494.
• Garcia-Gutierrez, M. S., et al. (2020). Cannabidiol: A potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules, 10(11), 1575.

Author: Dr. Jeff Bullock, PharmD | ORCID: 0009-0009-2053-4854

Bibliography

1. Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64, 21-47.
2. Friston, K. (2010). The free-energy principle: a unified brain theory? Nature Reviews Neuroscience, 11(2), 127-138.
3. Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344-1364.
4. Di Marzo, V. (2018). New approaches and challenges to targeting the endocannabinoid system. Nature Reviews Drug Discovery, 17(9), 623-639.
5. Fries, P. (2015). Rhythms for cognition: Communication through coherence. Neuron, 88(1), 220-235.

Full bibliography (100+ sources) available in the complete paper.